World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Number of total visits: 2804809

Number of visits today: 1080

Number of downloads: 2057907

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Morihara D, Ko YL, Shibata K, Yamauchi R, Fukuda H, Tsuchiya N, Fukunaga A, Kunimoto H, Iwashita H, Takata K, Tanaka T, Sakurai K, Inomata S, Yokoyama K, Nishizawa S, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S. IL28B gene polymorphism is correlated with changes in low-density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct-acting antiviral treatment. J Gastroenterol Hepatol 2019;34:2019-27. [PMID: 31144350 DOI: 10.1111/jgh.14741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]

For:

Morihara D, Ko YL, Shibata K, Yamauchi R, Fukuda H, Tsuchiya N, Fukunaga A, Kunimoto H, Iwashita H, Takata K, Tanaka T, Sakurai K, Inomata S, Yokoyama K, Nishizawa S, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S. IL28B gene polymorphism is correlated with changes in low-density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct-acting antiviral treatment. J Gastroenterol Hepatol 2019;34:2019-27. [PMID: 31144350 DOI: 10.1111/jgh.14741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]

Number	Citing Articles
1	Neokosmidis G, Protopapas AA, Stogiannou D, Filippidis A, Tziomalos K. Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C. Gastroenterología y Hepatología (English Edition) 2023;46:58-66. [DOI: 10.1016/j.gastre.2022.03.008] [Reference Citation Analysis]
2	Wang YK, Wang YW, Lu CL, Huang YH, Hou MC, Chang YL, Lee WP, Lan KH. Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol. Sci Rep 2022;12:9942. [PMID: 35705594 DOI: 10.1038/s41598-022-13657-5] [Reference Citation Analysis]
3	Wang YW, Lee WP, Huang YH, Hou MC, Lan KH. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. BMC Infect Dis 2021;21:984. [PMID: 34548026 DOI: 10.1186/s12879-021-06657-9] [Reference Citation Analysis]
4	Zidan AM, Saad EA, Ibrahim NE, Hashem MH, Mahmoud A, Hemeida AA. Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection. Heliyon 2021;7:e06908. [PMID: 34013078 DOI: 10.1016/j.heliyon.2021.e06908] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5	Huang CF, Dai CY, Yeh ML, Huang CI, Lee HC, Lai WT, Liang PC, Lin YH, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Chuang WL, Yu ML. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication. Kaohsiung J Med Sci. 2020;36:920-928. [PMID: 32643842 DOI: 10.1002/kjm2.12275] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]